The GLP-1 Telehealth Transparency Scorecard: What a Platform Should Show Before You Trust It

Last reviewed August 14, 2026. This educational scorecard evaluates what a service discloses—not whether a medication or provider is right for an individual. It is not medical advice, a clinical-quality rating, or an endorsement.

Presented By Our Partners

The new front door to weight-loss medicine often looks less like a clinic than a checkout page. A visitor answers a quiz, enters a card, and waits for a clinician whose name may not yet have appeared. Behind that polished screen may be a medical group, a pharmacy, a subscription contract, a lab workflow, a shipment, a side-effect protocol, and several layers of marketing.

Telehealth is not the problem. Hidden machinery is.

The GLP-1 Telehealth Transparency Scorecard is a way to slow the funnel down. It asks what a platform tells a prospective patient before payment: the exact medication category, who is clinically accountable, how the pharmacy can be verified, what the full price includes, what happens after prescribing, and which claims or placements are commercially influenced.

A high score means only that the relevant information was clear, specific, findable, and current on the review date. It does not establish clinical quality, medication authenticity, regulatory compliance, or suitability for any person.

The 20-point scorecard

Review ten domains. Give each one 0, 1, or 2 points:

• 0 — absent or confusing: the information is missing, contradictory, or blurred by the offer.
• 1 — partial: some information is present, but an important fact is vague, difficult to find, undated, or available only after payment.
• 2 — clear: the information is specific, easy to find before payment, internally consistent, and linked to a verifiable source where appropriate.

HDAI records the page, document, or database used for every point and the date it was checked. Unknown facts stay unknown. A company cannot buy points, improve its organic position through sponsorship, or convert a transparency score into an HDAI recommendation.

1. Medication identity and regulatory category

Two points require the offer to identify the medication or medication category and state whether the product is an FDA-approved finished drug, a compounded drug, or another category. The language must not present a compounded product as a generic version of an FDA-approved brand.

Why it matters: FDA says unapproved GLP-1 versions do not undergo its premarket review for safety, effectiveness, and quality. Its current consumer guidance lists as a telehealth red flag a claim that a compounded drug is “the same as” an FDA-approved drug.

Ask: If a clinician prescribes, what exact product category could I receive, and when will I know?

2. Prescriber identity and clinical accountability

Two points require a clear explanation of who evaluates the patient, who prescribes if appropriate, how licensure can be checked, and how the clinical team can be contacted after medication arrives. Coaching, customer support, and prescribing must not be presented as the same function.

FDA flags services that do not require screening and a prescription from a licensed doctor, or that do not make a licensed doctor available for questions after medication is received. The AMA’s ethics guidance likewise calls for identity verification, an assessment that telemedicine is appropriate, evaluation of the indication and safety of a prescription, documentation, and continuity of care.

Ask: Who owns the medical decision after the sale—and who responds if the plan needs to change?

3. Pharmacy identity and verification

Two points require the pharmacy pathway to be named or disclosed before dispensing, with a route to verify licensure. The platform should also explain what to do if a package is damaged, mislabeled, late, warm, or inadequately refrigerated.

FDA directs consumers to obtain prescriptions from a doctor and fill them at a state-licensed pharmacy. Its BeSafeRx resources link to state pharmacy boards and NABP’s online-pharmacy checking resources. FDA also reports fraudulent compounded-product labels and injectable GLP-1 shipments arriving warm or without adequate refrigeration.

Ask: Can I independently verify the dispensing pharmacy and confirm that it actually produced or dispensed the labeled medicine?

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

4. Complete price and billing terms

Two points require the service to show the realistic total price before payment: membership, clinician consultation, medication, labs, shipping, renewal, commitment period, cancellation, refund terms, and any early-termination fee. If cost varies by medication or dose, the range and reason for variation should be stated.

In its 2025 NextMed action, the FTC alleged that advertised monthly prices omitted the medication, required lab work, and clinician consultation, while a one-year commitment and early-termination terms were not adequately disclosed. The case is a useful category warning, not a finding about every telehealth service.

Ask: What would I actually pay in month one and over the first three months under the likely scenarios?

5. Screening and prescribing boundaries

Two points require the service to say that a quiz does not guarantee eligibility or a prescription and that an appropriately licensed clinician reviews medical history, current medications, risks, and the relevant indication. When a specific FDA-approved product is discussed, safety statements should track its current prescribing information rather than generic class shorthand.

Ask: What information is reviewed before a prescription decision, and what happens if telehealth is not appropriate?

6. Follow-up, continuity, and escalation

Two points require a visible follow-up cadence, a clinical contact route, a process for side effects and medication questions, and instructions for urgent or emergency concerns. A transparent service explains what happens when medicine is unavailable, unaffordable, not tolerated, or no longer clinically appropriate; it does not encourage self-directed dose changes.

The AMA treats continuity and follow-up as core telemedicine responsibilities. FDA tells patients with medicine questions to contact their doctor and, for labeling or instructions, the compounder or telehealth platform.

Ask: If I have a serious symptom, a dosing question, or a shipment problem, whom do I contact and what response window is promised?

7. Compounding-specific disclosure

Two points require the service to say plainly that compounded drugs are not FDA approved and are not reviewed by FDA before marketing for safety, effectiveness, or quality. The offer should identify the pharmacy, explain why compounding is being considered, disclose the active ingredient and dosage form, and avoid claims of sameness with an approved drug.

FDA’s current page also identifies specific concerns involving dosing errors, salt forms of semaglutide, fraudulent labels, adverse-event reporting, shipping temperature, and illegally marketed “research use” products. It states that retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition.

Ask: Why is a compounded drug being considered, what exactly is in it, and which licensed pharmacy is responsible?

8. Weight-loss and outcome claims

Two points require every consequential result claim to identify its evidence type and limits. A trial result must name the exact drug, dose or regimen where relevant, studied population, endpoint, duration, and comparator. Program data must not be presented as a randomized trial. A testimonial must not be presented as a typical outcome.

The FTC’s NextMed complaint alleged unsubstantiated average-loss claims and use of before-and-after images from people who were not customers. The proposed order requires competent and reliable evidence for average or typical-result claims.

Ask: Is this result from an FDA label, a peer-reviewed trial, the company’s own data, or one person’s story?

9. Reviews and testimonials

Two points require material incentives and relationships to be disclosed, testimonials to be authentic and permissioned, and review practices not to suppress legitimate criticism. Reviews may describe service experience; they cannot prove that a drug is authentic, appropriate, or safe for a particular person.

The FTC alleged that NextMed used fake testimonials, selectively challenged negative reviews, and offered incentives tied to changing or removing criticism. Those allegations show why review integrity belongs in a medical-service transparency score.

Ask: Are reviews being used as experience signals, or as a substitute for clinical evidence?

10. Sponsorship, ownership, and ranking influence

Two points require conspicuous disclosure of affiliate compensation, sponsorship, ownership interests, or other material relationships near the relevant claim or result. The service or publisher should explain why a platform appears and whether payment can affect placement.

For HDAI, the operating rule is explicit: sponsored eligibility and organic relevance are separate systems. Compensation cannot increase an organic score or rank. A sponsored card must be labeled as sponsored and cannot inherit editorial endorsement from this scorecard.

Ask: Am I seeing this result because it is relevant, because someone paid, or both?

How to read the total

The total is a map of disclosed information, not a verdict.

• 16–20: relatively high disclosure. Verification and clinical judgment are still required.
• 9–15: meaningful gaps remain. The domain notes should show exactly what is unclear.
• 0–8: substantial opacity. The score does not prove wrongdoing, but HDAI should not route a reader toward the service as a preferred result.

Some failures override the arithmetic. HDAI should withhold or remove a result when there is credible evidence of an illegal “research use” product sold for human use, a fraudulent pharmacy identity, no licensed-prescriber screening, fabricated reviews, undisclosed paid placement, or a compounded product marketed as identical to an FDA-approved drug. A missing fact is recorded as missing; it is not filled with inference.

What HDAI will publish with a future scored profile

Every public profile should show the review date, score by domain, cited evidence, unresolved questions, company correction channel, and change history. Operational facts such as prices, states served, pharmacy identity, and cancellation terms must be dated because they can change quickly. Clinical claims require authoritative or primary evidence. Provider-controlled pages may document the company’s own terms, but they cannot be the sole proof of efficacy or safety.

No profile should say “best GLP-1 telehealth company” merely because the disclosures are complete. The accurate language is narrower: here is what this service disclosed, what HDAI could verify, what remains unclear, and what a reader may want to ask a licensed clinician or pharmacist.

Why this belongs in the GLP-1 Intelligence Hub

The scorecard turns trust into a reusable product layer. Its fields can power provider profiles, comparison methodology, sponsor eligibility, directory routing, and chatbot answers without letting any of those systems make a patient-specific drug recommendation. It also gives readers a disciplined path from a marketing claim to the questions underneath it.

Start with the GLP-1 Intelligence Hub, then use the GLP-1 Claim Decoder to test a specific efficacy or safety claim.

The GLP-1 market has made access faster. Transparency has not always kept pace. Trust begins when the funnel stops hiding the machinery.

Sources

• U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed August 14, 2026.
• U.S. Food and Drug Administration. About BeSafeRx. Accessed August 14, 2026.
• U.S. Food and Drug Administration. BeSafeRx: Resources for Consumers. Accessed August 14, 2026.
• Federal Trade Commission. FTC Takes Action Against Telemedicine Firm NextMed. July 9, 2025; accessed August 14, 2026. Claims about NextMed above are identified as FTC allegations and proposed-order terms.
• American Medical Association Code of Medical Ethics. Ethical Practice in Telemedicine. Accessed August 14, 2026.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.